Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 09/29 | 09/30 | 9,500 sh12 trades | $477.42avg. | $4,535,479.91 | −2.8% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 09/28 | 09/29 | 9,500 sh14 trades | $480.85avg. | $4,568,106.28 | −2.8% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 09/25 | 09/28 | 9,500 sh9 trades | $476.17avg. | $4,523,635.17 | −2.8% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 09/24 | 09/25 | 9,500 sh11 trades | $473.55avg. | $4,498,752.59 | −2.8% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 09/23 | 09/24 | 9,500 sh12 trades | $491.57avg. | $4,669,917.55 | −2.8% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 09/22 | 09/23 | 9,500 sh10 trades | $494.83avg. | $4,700,850.59 | −2.8% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/29 | 06/30 | 9,500 sh10 trades | $545.80avg. | $5,185,126.21 | −19.0% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/26 | 06/29 | 9,500 sh14 trades | $543.97avg. | $5,167,736.78 | −19.0% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/25 | 06/26 | 9,500 sh11 trades | $550.40avg. | $5,228,773.4 | −19.0% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/24 | 06/25 | 9,500 sh8 trades | $548.69avg. | $5,212,526.79 | −19.0% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/22–06/23 | 06/24 | 19,000 sh14 trades | $540.85avg. | $10,276,097.22 | −31.9% |
United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/22 | 06/23 | 8,750 sh8 trades | $538.15avg. | $4,708,774.59 | −31.7% | |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/18 | 06/22 | 9,500 sh13 trades | $540.18avg. | $5,131,711.59 | −19.0% |
United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/18 | 06/22 | 10,000 sh14 trades | $540.15avg. | $5,401,506.62 | −34.6% | |
United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/18 | 06/18 | 8,300 sh11 trades | $541.55avg. | $4,494,853.3 | −15.5% | |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/17 | 06/18 | 9,500 sh8 trades | $552.40avg. | $5,247,802.81 | −19.0% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/16 | 06/17 | 9,500 sh10 trades | $549.80avg. | $5,223,058.18 | −19.0% |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/15 | 06/16 | 9,500 sh13 trades | $549.15avg. | $5,216,936.5 | −19.0% |
United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/15 | 06/16 | 10,000 sh14 trades | $549.17avg. | $5,491,740.58 | −34.6% | |
Chairperson & CEO | United TherapeuticsUTHR | Open-market sale10b5-1 plan | 06/12 | 06/15 | 9,500 sh9 trades | $541.39avg. | $5,143,207.13 | −19.0% |
